DVAX Dynavax Technologies Corporation

6.41
-0.02  -0%
Previous Close 6.43
Open 6.43
Price To Book 6.47
Market Cap 410220200
Shares 63,996,911
Volume 1,158,480
Short Ratio
Av. Daily Volume 1,204,579

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data to be presented at ASCO 2019. HNSCC presentation due June 01, 1:15 PM; Melanoma presentation June 03, 1:15 PM CT.
SD-101 + Pembrolizumab
Melanoma and head and neck squamous cell carcinoma (HNSCC)
CRL February 25, 2013 and November 14, 2016. Advisory Committee Meeting July 28, 2017 voted 21 -1 in favor of recommending approval. Final approval announced November 9, 2017.
HEPLISAV-B
Hepatitis B
Phase 2a trial did not meet primary endpoint - November 29, 2018.
AZD1419
Asthma
Phase 1/2 safety data presented at AACR April 2, 2019.
DV281
Non-small Cell Lung Cancer (NSCLC)

Latest News

  1. Dynavax to Present Data on Toll-like Receptor 9 Agonist SD-101 at the ASCO Annual Meeting 2019
  2. Investors Who Bought Dynavax Technologies (NASDAQ:DVAX) Shares Three Years Ago Are Now Down 66%
  3. After inking lease with cancer-fighting company, this new East Bay biotech project is full
  4. Dynavax Presents Phase 1b Data on Inhaled DV281 TLR9 Agonist at the 2019 AACR Annual Meeting
  5. The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial
  6. Dynavax Announces European Medicines Agency Accepts Marketing Authorization Application for HEPLISAV-B® for Prevention of Hepatitis B in Adults
  7. HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results
  8. Dynavax to Present on Inhaled TLR9 Agonist DV281 at the AACR Annual Meeting 2019
  9. Dynavax Exercises Option for $75 Million in Non-Dilutive Debt
  10. Why Dynavax Technologies Cratered in February
  11. Dynavax to Present at 39th Annual Cowen Healthcare Conference
  12. Edited Transcript of DVAX earnings conference call or presentation 26-Feb-19 9:30pm GMT
  13. Should You Be Concerned About Dynavax Technologies Corporation’s (NASDAQ:DVAX) Historical Volatility?
  14. Dynavax Technologies Corporation (DVAX) Q4 2018 Earnings Conference Call Transcript
  15. Dynavax Announces Fourth Quarter and Full Year 2018 Financial Results
  16. Dynavax Technologies to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on February 26
  17. Recent Analysis Shows Corcept Therapeutics, CDK Global, Dynavax Technologies, ICU Medical, American Vanguard, and Cabot Market Influences — Renewed Outlook, Key Drivers of Growth
  18. Why Dynavax Technologies Stock Marched Higher in January
  19. Heather Rowe Named Dynavax’s Vice President of Investor Relations and Corporate Communications
  20. Today's Research Reports on Trending Tickers: Dynavax Technologies and Tyme Technologies